- |||||||||| CTH522 / Statens Serum Institut, Imperial College London
Preclinical, Journal: Immune signature of Chlamydia vaccine CTH522/CAF (Pubmed Central) - Feb 28, 2024
Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF
- |||||||||| CTH522 / Statens Serum Institut, Imperial College London
Journal: Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. (Pubmed Central) - Dec 23, 2023
When testing this adjuvant in adult mice using the recombinant Chlamydia trachomatis (C.t.) vaccine antigen CTH522, it similarly enhanced IgG2a/c responses compared to DDA/TDB, but surprisingly reduced the magnitude of the IFN-?+Th1 response in a TLR7 agonist dose-dependent manner...Mixed bone marrow chimeras further demonstrated that this adjuvant did not require Th1 cells for IgG2a/c switching, but rather facilitated TLR7-dependent T-bet programming directly in B cells. This study underlines that adjuvant-directed IgG2a/c class-switching in vivo can occur in the absence of T-cell help, via direct activation of TLR7 on B cells and positions DDA/TDB/3M-052 as a powerful adjuvant capable of eliciting type I-like immunity in B cells without strong induction of Th1 responses.
- |||||||||| CTH522 / Statens Serum Institut, Imperial College London
Journal: Oral vaccination using microdevices to deliver α-GalCer adjuvanted vaccine afford mucosal immunity. (Pubmed Central) - Nov 15, 2022
Here, we test MCs, for oral delivery of the C. trachomatis vaccine candidate CTH522, in combination with effective mucosal adjuvants...This indicates that mice is not a suitable animal model for evaluation of MCs. These data should be taken into consideration in future in vivo trials with this and similar technologies, where larger animals might be a necessity for proof-of-concept studies.
- |||||||||| CTH522 / Statens Serum Institut, Imperial College London
Journal: Sublingual Boosting with A Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as A Strategy Against Chlamydia Trachomatis. (Pubmed Central) - Jun 11, 2022
Meanwhile the fast gelation at body temperature together with rapid antigen release should avoid CTH522 leakage by swallowing and increase the contact with sublingual tissue, thus promoting absorption. In vivo studies demonstrated that parenteral-sublingual prime-boost immunization, using CAF01 and OGEL as CTH522 vaccine carriers, showed a tendency to increase cellular (Th1/Th17) immune responses when compared to mucosal or parenteral vaccination alone. Furthermore, parenteral prime with CAF01/CTH522 followed by sublingual boosting with OGEL/CTH522 elicited a local IgA response in the genital tract.
- |||||||||| CTH522 / Statens Serum Institut, Imperial College London
Trial completion: CHLM-02: Safety and Immunogenicity of a Chlamydia Vaccine CTH522 (clinicaltrials.gov) - May 5, 2022
P1, N=65, Completed,
Furthermore, parenteral prime with CAF01/CTH522 followed by sublingual boosting with OGEL/CTH522 elicited a local IgA response in the genital tract. Recruiting --> Completed
- |||||||||| CTH522 / Statens Serum Institut, Imperial College London
Trial completion date, Trial primary completion date: CHLM-02: Safety and Immunogenicity of a Chlamydia Vaccine CTH522 (clinicaltrials.gov) - Mar 18, 2021
P1, N=66, Recruiting,
Recruiting --> Completed Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Dec 2020 --> Jan 2022
- |||||||||| CTH522 / Statens Serum Institut, Imperial College London
Enrollment open, Trial initiation date: CHLM-02: Safety and Immunogenicity of a Chlamydia Vaccine CTH522 (clinicaltrials.gov) - Mar 6, 2020
P1, N=66, Recruiting,
Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Dec 2020 --> Jan 2022 Not yet recruiting --> Recruiting | Initiation date: Nov 2019 --> Feb 2020
|
